Corona Remedies Ltd (CORONA) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management reaffirmed its revenue growth guidance of 1.5x the IPM, suggesting potential upside to the 15% forecast as the market is currently growing at 10-12%.
- Future M&A will target entry into new therapies like nephrology and CNS, not just filling gaps, with five specific areas identified for inorganic growth.
- The company's revenue from products under price control (NLEM) is only 7.5%, and none of its top five brands are affected, mitigating pricing regulation risks.
Performance Overview
- Delivered strong revenue growth of 22% year-on-year in Q2 FY27, significantly outperforming the Indian Pharmaceutical Market (IPM).
- Chronic portfolio grew by approximately 29%, nearly double the growth of the corresponding market segment.
- The company has consistently grown at 1.9x the IPM over the last three years, driven by volume growth, new introductions, and price increases.
- Successfully initiated expansion into the infertility therapeutic area with a dedicated task force, showing promising early results.
- Maintained a strong position as one of the fastest-growing companies in the IPM, ranking 26th overall and 14th in the covered market.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.